The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.

The market expects ANI Pharmaceuticals (ANIP) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus ...

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

Some 20 travel staff at the FDA, who made arrangements for the regulator’s inspectors, will be getting their jobs back, as ...

If the FDA deems Pfizer’s and Moderna’s updated vaccines “new” products, it’s extremely unlikely the doses would be ready for ...

Shares of Novavax Inc. NVAX slipped 3.90% to $6.41 Thursday, on what proved to be an all-around great trading session for the ...

Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.

A major change in the way HHS plans to evaluate vaccine safety is raising fears that approvals will become unnecessarily ...

Ionis Pharmaceuticals unveiled results from a survey conducted by The Harris Poll showing that 91% of surveyed adults living ...

The new policy, revealed by the Department of Health and Human Services on Wednesday, would make vaccines “less available and ...

On a Thursday conference call with investors, Moderna CFO Jamey Mock outlined a roadmap for the mRNA specialist to lower its ...

“Under Secretary Kennedy’s leadership, all new vaccines will undergo safety testing in placebo-controlled trials prior to ...